Securing the indication of the world's first long-acting growth hormone ISS globally, is there a solution to the situation of both revenue and net profit decline at Changchun High-tech Industries? | Announcement for quick reading
①On the 5th, changchun high-tech industries announced that its long-acting growth hormone has been approved for ISS indication. In August of this year, this variety was also approved for the growth disorder in girls with gonadal dysgenesis (Turner syndrome); ②In the first three quarters of this year, changchun high-tech industries' performance and profitability both declined. Whether the main products that have been on the market for 10 years can have new sales volume is widely watched.
R&D expenses continue to rise, autobio diagnostics once again embroiled in a whirlpool of disputes | interpretations
①In the first three quarters of this year, the revenue and net income attributable to shareholders of Autobio Diagnostics have both increased to a certain extent; ②The company has further increased its investment in research and development, with multiple products obtaining medical instruments registration certificates.
Sales of the herpes zoster vaccine declined, dragging down Bacillus's third-quarter revenue by over 40%.
① Due to the reduction in sales of attenuated live herpes zoster vaccine, Baike Biotechnology achieved a year-on-year decrease in revenue of 40.37% in the third quarter, with a year-on-year decrease in net income attributable to the parent company of 51.41%; ② Currently, in addition to GSK's herpes zoster vaccine competing with Baike Biotechnology in the domestic market, there are over 10 companies developing similar products, Baike Biotechnology faces multiple potential competitors.
IVD sector growth cannot hide the decline in performance. Q0.03 million Tai Biological net profit plummeted more than 90%. | Interpretations
①Affected by market adjustments, government centralized procurement, etc., beijing wantai biological pharmacy enterprise's biological vaccine sector continues to drag down the company's performance. ② The company's diagnostic sector business has grown, and the chemiluminescence product line maintained rapid double-digit growth compared to the same period last year. ③ With factors such as increased investment in industrialization of the nine-valent HPV vaccine, beijing wantai biological pharmacy enterprise's revenue and net profit attributable to the parent company decreased significantly in the first three quarters.
The hottest summer Artemisia annua is not selling well chongqing taiji industry Q3 performance decreased by 70% | interpretations
In 2024, the national average temperature is the highest for the same period in history since 1961, but the sales volume of Chongqing Taiji Industry Huoxiang Zhengqi Oral Liquid decreased significantly in the third quarter, with a sharp drop in sales of the main product, leading to a year-on-year decline of over 70% in Chongqing Taiji Industry's profit in the third quarter.
The performance decline continues, tonghua dongbao pharmaceutical's Q3 sales expenses exceed 0.3 billion yuan|interpretations
Due to factors such as a significant decrease in revenue and the termination of research and development pipelines, tonghua dongbao pharmaceutical handed in a loss-making third-quarter report. From the perspective of Q3 performance, the company's revenue shows a certain recovery trend, but the escalating sales expenses quarter by quarter have resulted in a situation of "increased revenue without increased profits".